Abstracts Archive - Page 1370 of 2607 - ACR Meeting Abstracts

Abstract Number: 2757 • 2018 ACR/ARHP Annual Meeting
A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Navita L. Mallalieu¹, John H. Stone², Peter M. Villiger³, Micki Klearman⁴, Laura Brockwell⁵, Sophie Dimonaco⁵ and Jean Eric Charoin⁶, ¹Roche Innovation Center, New York, NY, ²Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³University of Bern, Bern, Switzerland, ⁴Genentech, Inc., South San Francisco, CA, ⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁶Roche Innovation Center (Basel), Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ), an anti–interleukin-6 receptor (IL-6R) monoclonal antibody, was recently approved for the treatment of patients with giant cell arteritis (GCA) based on results…
Abstract Number: 2758 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
Carlotta Nannini¹, Laura Niccoli², Emanuele Antonio Maria Cassarà², Olga Kaloudi², Stelvio Sestini³ and Fabrizio Cantini², ¹Prato Hospital, Prato, Italy, ²Rheumatology, Prato Hospital, Prato, Italy, ³Radiology, Prato Hospital, Prato, Italy
Background/Purpose: The efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, in patients with refractory GCA has been demonstrated. The purpose of this study was…
Abstract Number: 2759 • 2018 ACR/ARHP Annual Meeting
Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis
Shubhasree Banerjee¹, Kaitlin Quinn², Katherine B. Gribbons³, Joel S. Rosenblum⁴, Ali Civelek⁵, Elaine Novakovich⁶, Armin Bagheri¹, Peter A. Merkel⁷, Mark A. Ahlman⁸ and Peter C. Grayson⁹, ¹Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Skin and Musculoskeletal Disease, Bethesda, MD, ⁴NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ⁵National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁹National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET),…
Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Sebastian H. Unizony¹, Jinglan Pei², Páris N. Sidiropoulos², Jennie H. Best², Christine Birchwood² and John H. Stone³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, CA, ³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
Abstract Number: 2761 • 2018 ACR/ARHP Annual Meeting
High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort
Sarah H. Chung¹, Meredith B. Morcos¹ and Bernard Ng^1,2, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Temporal artery biopsy (TAB) currently remains the gold-standard confirmatory test for the diagnosis of giant cell arteritis (GCA); positive TAB justifies long-term steroid use…
Abstract Number: 2762 • 2018 ACR/ARHP Annual Meeting
A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort
Sarah H. Chung¹, Meredith B. Morcos¹ and Bernard Ng^1,2, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: TAB is currently considered the gold standard for the diagnosis of GCA. However, it is suspected that the sensitivity of TAB is limited by…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 2764 • 2018 ACR/ARHP Annual Meeting
Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data
Valérie Devauchelle-Pensec¹, Eric Hachulla², Marc Paccalin³, Sophie Gandon⁴, Isabelle Idier⁵, Maeva Nolin⁶, Manon Belhassen⁶ and Alfred Mahr⁷, ¹Department of Rheumatology and Unit of Immunology, University Medical School, Brest, France, ²Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ³Department of Geriatric Medicine, University Hospital, Poitiers, France, ⁴Clinical Operation, Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶PELyon, Pharmacoepidemiologie, Lyon, France, ⁷Hospital Saint-Louis, University Paris Diderot, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated, primary systemic vasculitis that affects large and medium-sized arteries. GCA may cause vision loss in up to…
Abstract Number: 2765 • 2018 ACR/ARHP Annual Meeting
Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort
Rok Jese, Ziga Rotar, Matija Tomsic and Alojzija Hočevar, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: The inflammation of thyroid arteries (ThA) is not commonly considered and investigated in giant cell arteritis (GCA). We aimed to estimate the frequency of…
Abstract Number: 2766 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study
Shafay Raheel¹, Cynthia S. Crowson² and Eric L. Matteson³, ¹St. Joseph's Hospital, Chicago, IL, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: To determine whether there is a seasonal peak onset of giant cell arteritis (GCA). We examined the seasonal variability of GCA in a geographically-defined…
Abstract Number: 2767 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study
Shafay Raheel¹, Cynthia S. Crowson² and Eric L. Matteson³, ¹St. Joseph's Hospital, Chicago, IL, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: The presence of varicella zoster virus (VZV) signal in the temporal arteries of patients with giant cell arteritis has suggested a possible role of…
Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Elisheva Pokroy-Shapira¹, Ariela Dortort-Lazar^2,3 and Yair Molad^4,5, ¹Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Beilinson hospital Rabin Medical Center, Petah Tikva, Israel, ³Sackler Faculty of Medicine Tel Aviv university, Tel Aviv, Israel, ⁴Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…
Abstract Number: 2769 • 2018 ACR/ARHP Annual Meeting
A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients
Ammar Haikal¹, Garth Fraga², Jason Springer¹ and Mehrdad Maz³, ¹Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, ²The University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, ³Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Giant cell arteritis (GCA) is a systemic vasculitis of large and medium-sized arteries mostly reported in Caucasians (CCs) over 50 y.o. There is limited…
Abstract Number: 2770 • 2018 ACR/ARHP Annual Meeting
The Effect of Metabolic Syndrome on Giant Cell Arteritis Treatment
Weixia Guo¹, Roman Jandarov² and Gaurav Gulati³, ¹Internal Medicine, University of Cincinnati, Cincinnati, OH, ²Environmental Health, University of Cincinnati, Cincinnati, OH, ³Rheumatology, University of Cincinnati, Cincinnati, OH
Background/Purpose: The effects of metabolic syndrome on vasculature are complex, and studies exploring the role of metabolic syndrome (including diabetes mellitus, obesity, hypertension, and hyperlipidemia)…
Abstract Number: 2771 • 2018 ACR/ARHP Annual Meeting
Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study
Mohammed Bari¹, Anthony Ocon², Mohamed Tageldin¹, Mirrah Mumtaz¹, Muhammad Saad Shaukat¹, Paul Feustel¹, Ruben Peredo², Peter C. Grayson³ and Shubhasree Banerjee^1,4,5, ¹Albany Medical Center, Albany, NY, ²Medicine, Albany Medical Center, Albany, NY, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴The Center for Rheumatology, Albany, NY, ⁵Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis affecting individuals over 50 years of age. Multiple epidemiological studies have determined increased risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].